Investment
Features
FeesSafety
Academy
More
Pluang+

Orka stock jumps nearly 19% on strong Phase 2a trial results and Barclays upgrade

Analyst Insights
27 Apr 2026
Stuart Mooney
View Source
Bullish
pluang ai news

Orka's stock surged 18.93% to a 52-week high after positive Phase 2a trial results for its drug ORKA-001 showed a 63.5% complete skin clearance rate in psoriasis patients. Barclays upgraded Orka to "Overweight" and raised its price target from $78 to $160, reflecting strong confidence in the biotech's future. The drug also demonstrated a favorable safety profile, supporting its potential as a new treatment for moderate-to-severe plaque psoriasis. This boost signals growing investor optimism for Orka's clinical progress and market prospects.

More News (BCS)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App